Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife

Award Information
Agency:
Department of Agriculture
Amount:
$346,000.00
Program:
SBIR
Contract:
2007-33610-18486
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2007
Phase:
Phase II
Agency Tracking Number:
2006-00528
Solicitation Topic Code:
N/A
Small Business Information
Molecular Targeting Technologies, Inc.
882 S. Matlack Street Suite 105, West Chester, PA, 19382
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Jeffrey Mattis
 Sr. Vice President, Scientific Affairs
 (610) 738-7938
 jmattis@mtarget.com
Business Contact
 Koon Pak
Title: President and CEO
Phone: (610) 738-7938
Email: cpak@mtarget.com
Research Institution
N/A
Abstract
Oral immunization of wildlife and stray dogs with live vaccines is the only effective method to control rabies in carnivore species worldwide. Because adenoviruses replicate on mucosal surfaces, they represent excellent vectors that can be administered both orally and intranasally. The nearly ideal vaccine vector for immunization of carnivores against rabies would be the canine adenovirus type 2 (CAV 2) virus. The CAV 2 vaccine is a very effective livemodified vaccine which has an excellent safety record and which is being used worldwide for the routine vaccination of dogs against both CAV 1 and CAV 2. Although this vaccine is usually administered subcutaneously, it is also effective when administered orally and may allow for limited animal to animal transmission. Previous phase I efforts demonstrated the initial proof of concept through successful construction and selection of CAV 2-RVG viruses followed by evaluation of safety and protective activity in laboratory animals. In this Phase II project we propose to continue evaluation of the vaccine candidate through optimization of virus growth and production of a research viral seed (RVS) stock, genetic and thermal stability studies, in vitro and in vivo safety studies, and safety and efficacy studies in target animals. It is likely that CAV2-RVG will be immunogenic by the oral route in target animals resulting protective immunity against rabies. A key concern to be addressed in this project is the safety of the recombinant virus in target and non-target animals.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government